Healthcare / Pharmaceutical RetailersStockholm
$73.10
+0.95 (+1.32%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 21%
FCF escenarios
weak_data · normalized FCF $94.7M · quality 44.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
51/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$7.6B
P/E
32.2x
↑EV/EBITDA
17.0x
↑ROE
27.1%
↑Gross Margin
26.9%
↓Debt/Equity
0.39
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+13.8%
FCF CAGR
—
FCF margin
1.6%
FCF / Net income
0.51x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $7.20B · net income $228.7M · FCF $117.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $7.20B | $7.20B | $6.54B | $5.45B | $4.88B |
| Net Income | $228.7M | $228.7M | $214.9M | $87.0M | $19.9M |
| EBITDA | $464.1M | $464.1M | $399.6M | $226.0M | $104.8M |
| EPS | 2.20 | 2.20 | 2.09 | 0.84 | 0.19 |
| Gross Margin | 26.9% | 26.9% | 27.3% | 26.6% | 26.0% |
| Operating Margin | 4.2% | 4.2% | 4.0% | 2.1% | 1.0% |
| Net Margin | 3.2% | 3.2% | 3.3% | 1.6% | 0.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.39 | 0.39 | 0.39 | 0.65 | 1.02 |
| Current Ratio | 1.34 | 1.34 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $117.7M | $117.7M | $42.4M | $94.7M | $-110.6M |
| Returns | |||||
| ROE | 27.1% | 27.1% | 34.9% | 21.6% | 6.1% |
| Valuation | |||||
| P/E | 32.20 | 32.20 | 40.96 | — | — |
| EV/EBITDA | 17.05 | 17.05 | 22.51 | — | — |
| P/B | 9.02 | 9.02 | 14.27 | — | — |
| Growth & Yield | |||||
| Revenue Growth | 10.1% | 10.1% | 20.0% | 11.6% | — |
| EPS Growth | 5.3% | 5.3% | 150.0% | 337.2% | — |
| Dividend Yield | 0.8% | 0.8% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
43.4%
EPS terminal req.
$6.49
Spread vs growth
-38.1%
5Y implied EPS CAGR
29.0%
EPS terminal req.
$7.85
Spread vs growth
-23.7%
10Y implied EPS CAGR
19.1%
EPS terminal req.
$12.64
Spread vs growth
-13.8%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-25.7%
Start / end P/E
47.6x → 33.2x
EPS bridge
2.09 → 2.20
Residual
-1.6%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.